New Automated Assay Measures Levels of sPLA2-IIA
|
By LabMedica International staff writers Posted on 08 Apr 2019 |
|
Image: The diagram shows how sPLA2-IIA binding to anionic phospholipids leads to its activation and promotes inflammation. The oxidation of the phospholipids produces stress, which causes the anionic phospholipids phosphatidylserine (PS) and phosphatidylethanolamine (PE) to be transported to the outer leaflet. This reaction activates cationic sPLA2-IIA. The higher activity of sPLA2-IIA promotes the hydrolysis of the outer leaflet phospholipids into arachidonic acid and lysophospholipids. Through the cyclooxygenase and 5-lipoxygenase enzymes, arachidonic acid is converted into prostaglandins, leukotrienes, and other inflammatory eicosanoids (Photo courtesy of Randox).
Phospholipase A2 (PLA2s) are a family of enzymes that cleave the fatty acid in position two of phospholipids, hydrolyzing the bond between the second fatty acid “tail” and the glycerol molecule. Of particular interest is the secreted phospholipase (sPLA2-IIA) that specifically recognizes the sn-2 acyl bond of phospholipids and catalytically hydrolyzes the bond, releasing arachidonic acid and lysophosphatidic acid. Upon downstream modification by cyclooxygenases, arachidonic acid is modified into active eicosanoid compounds, including prostaglandins and leukotrienes.
sPLA2-IIA has been shown to promote inflammation in mammals by catalyzing the first step of the arachidonic acid pathway by breaking down phospholipids, resulting in the formation of fatty acids including arachidonic acid. This arachidonic acid is then metabolized to form several inflammatory and thrombogenic molecules. Elevated levels of sPLA2-IIA are thought to contribute to several inflammatory diseases, and have been shown to promote vascular inflammation correlating with disease risk in coronary artery disease and acute coronary syndrome. Unlike traditional cardiac biomarkers used to predict adverse outcomes in patients, sPLA2-IIA has been shown to act at multiple pathways involved in atherogenesis, from lipid oxidation to modulation of vascular inflammatory cell activation and apoptosis. Measurement of sPLA2-IIA enables clinicians to gain a comprehensive overview of cardiac risk and may help to tailor treatment accordingly.
Recognizing the link between the secreted phospholipases and coronary disease risk, Randox (Crumlin, United Kingdom) has introduced an automated assay (currently for research use only) to measure levels of sPLA2-IIA. This automated assay eliminates the inconvenient and time consuming traditional ELISA based test for sPLA2-IIA.
The Randox sPLA2-IIA Assay was designed for use on a wide range of clinical chemistry analysers, and applications are available detailing instrument-specific settings. The latex enhanced immunoturbidimetric assay kit contains liquid ready-to-use reagents for convenience and ease-of-use. In addition, controls and calibrators are available offering a complete testing package. The addition of the sPLA2-IIA Assay compliments the existing cardiac risk panel from Randox, providing a different outlook and method of assessing cardiac concerns in patients.
sPLA2-IIA has been shown to promote inflammation in mammals by catalyzing the first step of the arachidonic acid pathway by breaking down phospholipids, resulting in the formation of fatty acids including arachidonic acid. This arachidonic acid is then metabolized to form several inflammatory and thrombogenic molecules. Elevated levels of sPLA2-IIA are thought to contribute to several inflammatory diseases, and have been shown to promote vascular inflammation correlating with disease risk in coronary artery disease and acute coronary syndrome. Unlike traditional cardiac biomarkers used to predict adverse outcomes in patients, sPLA2-IIA has been shown to act at multiple pathways involved in atherogenesis, from lipid oxidation to modulation of vascular inflammatory cell activation and apoptosis. Measurement of sPLA2-IIA enables clinicians to gain a comprehensive overview of cardiac risk and may help to tailor treatment accordingly.
Recognizing the link between the secreted phospholipases and coronary disease risk, Randox (Crumlin, United Kingdom) has introduced an automated assay (currently for research use only) to measure levels of sPLA2-IIA. This automated assay eliminates the inconvenient and time consuming traditional ELISA based test for sPLA2-IIA.
The Randox sPLA2-IIA Assay was designed for use on a wide range of clinical chemistry analysers, and applications are available detailing instrument-specific settings. The latex enhanced immunoturbidimetric assay kit contains liquid ready-to-use reagents for convenience and ease-of-use. In addition, controls and calibrators are available offering a complete testing package. The addition of the sPLA2-IIA Assay compliments the existing cardiac risk panel from Randox, providing a different outlook and method of assessing cardiac concerns in patients.
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Repetitive Pipette
VWR® Stepper Pro
Latest Clinical Chem. News
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
Channels
Molecular Diagnostics
view channel
Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition whose incidence is rising in industrialized and newly industrialized countries, with prevalence in early‑industrialized... Read more
FDA Clears At-Home HPV Test with Extended Genotyping for Cervical Screening
Cervical cancer is largely preventable through regular screening and early detection of human papillomavirus (HPV), which causes nearly all cases. Yet roughly 60% of cervical cancers occur in people who... Read more
Hematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Immunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Microbiology
view channel
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
Pathology
view channel
AI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read more
